Multiple Sclerosis, Melatonin, and Neurobehavioral Diseases

Multiple Sclerosis, Melatonin, and Neurobehavioral Diseases

Bibliographic Details
Main Author:	Richard Wurtman
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2017-10-01
Series:	Frontiers in Endocrinology
Subjects:	melatonin multiples sclerosis light darkness seasonal affective disorder syndrome neurodegeneration
Online Access:	http://journal.frontiersin.org/article/10.3389/fendo.2017.00280/full

Similar Items

Multiple Sclerosis, Melatonin, and Neurobehavioral Diseases
by: Wurtman, Richard Jay
Published: (2018)

Impact of Melatonin on Motor, Cognitive and Neuroimaging Indices in Patients with Multiple Sclerosis
by: Tina Roostaei, et al.
Published: (2015-11-01)

Decreased Urinary Level of Melatonin as a Marker of Disease Severity in Patients with Multiple Sclerosis
by: Taha Gholipour, et al.
Published: (2015-02-01)

Evaluation of the Serum Melatonin Levels in the Treatment of Patients with Multiple Sclerosis
by: Abbas Alimoradian, et al.
Published: (2018-05-01)

Serum levels of melatonin and cytokines in multiple sclerosis
by: Naser Farhadi, et al.
Published: (2014-04-01)

Protocol for a randomized, double blind, placebo controlled, crossover trial of Melatonin for treatment of Nocturia in adults with Multiple Sclerosis (MeNiMS)
by: D. Delgado, et al.
Published: (2017-03-01)

A rapid review of differences in cerebrospinal neurofilament light levels in clinical subtypes of progressive multiple sclerosis
by: Haritha L. Desu, et al.
Published: (2024-04-01)

Deciphering Multiple Sclerosis Progression
by: Virginia Meca-Lallana, et al.
Published: (2021-04-01)

Metformin as a Potential Agent in the Treatment of Multiple Sclerosis
by: Angela Dziedzic, et al.
Published: (2020-08-01)

Mitochondrial Dysfunction and Multiple Sclerosis
by: Isabella Peixoto de Barcelos, et al.
Published: (2019-05-01)

Effects of long-term light, darkness and oral administration of melatonin on serum levels of melatonin
by: Naser Farhadi, et al.
Published: (2016-02-01)

Melatonin: Countering Chaotic Time Cues
by: Josephine Arendt
Published: (2019-07-01)

Results of a randomized, double blind, placebo controlled, crossover trial of melatonin for treatment of Nocturia in adults with multiple sclerosis (MeNiMS)
by: Marcus J. Drake, et al.
Published: (2018-08-01)

Yoga as an intervention to manage multiple sclerosis symptoms
by: Priyanka Thakur, et al.
Published: (2020-04-01)

Neurodegeneration and its potential markers in the diagnosing of secondary progressive multiple sclerosis. A review
by: Aleksandra Pogoda-Wesołowska, et al.
Published: (2023-09-01)

Steps in Multiple Sclerosis Pathogenesis - II: The Role of Biological Markers, Sodium Channels and Glutamate in Neurodegeneration
by: Ömer Faruk Aydın, et al.
Published: (2006-04-01)

Running on Empty: Of Hypopinealism and Human Seasonality
by: Dieter Kunz, et al.
Published: (2021-10-01)

Latitude, Vitamin D, Melatonin, and Gut Microbiota Act in Concert to Initiate Multiple Sclerosis: A New Mechanistic Pathway
by: Majid Ghareghani, et al.
Published: (2018-10-01)

Concurrent multiple sclerosis and amyotrophic lateral sclerosis: where inflammation and neurodegeneration meet?
by: Li Grace, et al.
Published: (2012-01-01)

Multiple Sclerosis: Inflammatory and Neuroglial Aspects
by: Giulio Papiri, et al.
Published: (2023-02-01)

Melatonin Therapy Modulates Cerebral Metabolism and Enhances Remyelination by Increasing PDK4 in a Mouse Model of Multiple Sclerosis
by: Majid Ghareghani, et al.
Published: (2019-02-01)

Melatonin improves memory defects in a mouse model of multiple sclerosis by up-regulating cAMP-response element-binding protein and synapse-associated proteins in the prefrontal cortex
by: Badrah Saeed Alghamdi, Hanin Abdulbaset AboTaleb
Published: (2020-06-01)

Comparative Analysis of Neurodegeneration and Axonal Dysfunction Biomarkers in the Cerebrospinal Fluid of Patients with Multiple Sclerosis
by: Agnieszka Kulczyńska-Przybik, et al.
Published: (2022-07-01)

Immunosenescence and multiple sclerosis: inflammaging for prognosis and therapeutic consideration
by: Smathorn Thakolwiboon, et al.
Published: (2023-10-01)

Autophagy in Multiple Sclerosis: Two Sides of the Same Coin
by: Chairi Misrielal, et al.
Published: (2020-11-01)

Cytokine Gene Expression in Newly Diagnosed Multiple Sclerosis Patients
by: Seyed Javad Hasheminia, et al.
Published: (2015-04-01)

New possibilities of siponimod therapy in patients with secondary progressive multiple sclerosis
by: D. S. Kasatkin, et al.
Published: (2021-02-01)

Aging, Cellular Senescence, and Progressive Multiple Sclerosis
by: Dimitrios Papadopoulos, et al.
Published: (2020-06-01)

Migraine headache in Multiple Sclerosis. Is more frequent among MS patients?
by: Alia Saberi, et al.
Published: (2023-03-01)

Relationship between Mitochondrial Dysfunction and Multiple Sclerosis: A Review Study
by: Narges Karimi, et al.
Published: (2015-07-01)

A Randomized Control Trial Study to Determine the Effect of Melatonin on Serum Levels of IL-1β and TNF-α in Patients with Multiple Sclerosis
by: Masoomeh Yosefifard, et al.
Published: (2019-11-01)

Adipokines as Immune Cell Modulators in Multiple Sclerosis
by: Merel Rijnsburger, et al.
Published: (2021-10-01)

Fatty acids role in multiple sclerosis as “metabokines”
by: Haojun Yu, et al.
Published: (2022-06-01)

The Seasonal Fluctuation of Fatigue in Multiple Sclerosis
by: Matthias Grothe, et al.
Published: (2022-06-01)

Diagnostic biomarkers of multiple sclerosis
by: Mohammad Asgharzadeh, et al.
Published: (2021-12-01)

Therapeutic Advances in Multiple Sclerosis
by: Jennifer H. Yang, et al.
Published: (2022-06-01)

The Possible Role of Neural Cell Apoptosis in Multiple Sclerosis
by: Peter G. E. Kennedy, et al.
Published: (2022-07-01)

Pseudobulbar Affect in Multiple Sclerosis Patients
by: Viktor Vidović, et al.
Published: (2015-01-01)

Multiple Sclerosis and the Endogenous Opioid System
by: Zoë Dworsky-Fried, et al.
Published: (2021-09-01)

Thalamic Injury and Cognition in Multiple Sclerosis
by: Moein Amin, et al.
Published: (2021-02-01)